Kisspeptin Protocol: Complete Cycling & Dosing Guide

Overview

Kisspeptin-10 is a neuropeptide that acts as the master regulator of your hypothalamic-pituitary-gonadal (HPG) axis. Unlike direct hormone replacement or GnRH agonists, kisspeptin works upstream by binding to KISS1R receptors on GnRH neurons, triggering a natural, pulsatile release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This mechanism preserves physiological signaling patterns while avoiding the desensitization risk associated with continuous GnRH agonist exposure.

Primary applications:

• Restoring endogenous testosterone production post-anabolic steroid cycles
• Recovering suppressed fertility and gonadal function
• Supporting hypogonadism recovery protocols
• Managing HPG axis dysfunction from various causes

Kisspeptin exists in regulatory gray areas in most jurisdictions and is not approved as a therapeutic drug outside research contexts. The evidence base is strongest for reproductive hormone stimulation, with mechanistic promise for metabolic and immune applications, but limited human efficacy data outside the reproductive domain.

Standard Protocol

Baseline Dosing Framework

Injectable (subcutaneous injection):

• Dose range: 50–150 mcg per injection
• Frequency: Once daily or every other day
• Administration: Subcutaneous injection, typically in the abdomen or thigh
• Onset: Peak LH response occurs 15–30 minutes post-injection; sustained elevation over 60–90 minutes

Intranasal:

• Dose range: 1–3 mg per administration
• Frequency: Once daily
• Onset: Slower than injection but still effective; useful for convenience and avoiding injection site irritation

Standard Cycle Structure

The most common protocol follows an 8–12 week cycle, structured as follows:

• Weeks 1–4: Build phase (dose escalation or stabilization)
• Weeks 5–10: Maintenance phase (consistent dosing to maximize HPG axis recovery)
• Weeks 11–12: Taper phase (optional; allows gradual downregulation to support endogenous production)
• Post-cycle: 4–8 weeks off to assess recovery and allow pituitary sensitivity reset

Goal-Specific Protocols

Protocol A: Post-Steroid Cycle Recovery (HPTA Restoration)

Objective: Restore natural LH, FSH, and testosterone production after anabolic steroid use.

Cycle length: 10–12 weeks

Dosing:

• Weeks 1–2: 50 mcg every other day (3 injections per week)
• Weeks 3–6: 75–100 mcg daily
• Weeks 7–10: 100–150 mcg daily
• Weeks 11–12: 75 mcg every other day (taper phase)

Rationale: The gradual escalation minimizes shock to the system while building pituitary sensitivity. Higher doses during the middle phase drive maximal LH/FSH release, promoting Leydig cell recovery. The taper allows the axis to begin independent signaling before cessation.

Monitoring: Track morning testosterone levels every 2–3 weeks. LH and FSH should rise progressively; expect baseline testosterone recovery to 70–80% by week 8–10.

Protocol B: Fertility & Germ Cell Recovery

Objective: Restore spermatogenesis and reproductive capacity in suppressed males.

Cycle length: 12 weeks minimum (spermatogenesis takes ~74 days)

Dosing:

• Weeks 1–3: 75 mcg daily
• Weeks 4–12: 100–125 mcg daily

Rationale: Sustained daily dosing provides consistent FSH stimulation necessary for spermatogenesis. Slightly lower doses than HPTA recovery avoid excessive LH surges that can paradoxically suppress FSH-driven germ cell production at supraphysiologic levels.

Monitoring: Semen analysis at baseline and week 12. Expect progressive motility and count improvement; total sperm count recovery may require 8–12 weeks post-cessation due to continued spermatogenesis maturation.

Protocol C: Metabolic & Energy Optimization

Objective: Leverage kisspeptin's role in metabolic-reproductive coupling to support energy, insulin sensitivity, and fat loss context.

Cycle length: 8–10 weeks

Dosing:

• Weeks 1–3: 50 mcg every other day
• Weeks 4–10: 75 mcg daily

Rationale: Kisspeptin modulates glucose-stimulated insulin secretion and energy homeostasis; consistent dosing supports metabolic signaling. Lower overall doses avoid excessive gonadal steroid production, which may interfere with fat loss protocols.

Note: Evidence for direct fat loss is Tier 2 (mechanistic, not proven in human RCTs). Use as supportive therapy within a caloric deficit and training protocol, not as primary intervention.

Protocol D: Joint Health & Anti-Aging

Objective: Exploit kisspeptin's in-vitro anti-senescence effects in chondrocytes and potential anti-inflammatory signaling.

Cycle length: 12 weeks (longer duration for tissue remodeling)

Dosing:

• Weeks 1–12: 75–100 mcg daily

Rationale: Sustained dosing maintains kisspeptin's SIRT1-dependent anti-senescence pathway and TNF-α suppression in chondrocytes. Consistent hormone levels also support anabolic signaling in connective tissues.

Note: This is exploratory protocol use. Evidence is in-vitro and animal-based. Combine with evidence-based joint support (collagen, hyaluronic acid, strength training) for best outcomes.

How to Administer: Step-by-Step

Injectable Administration (Subcutaneous)

1. Prepare the injection site: Clean a 2–3 inch area of skin (typically lower abdomen, 2 inches lateral to navel, or lateral thigh) with alcohol prep pad. Allow to air dry 10–15 seconds.

2. Reconstitute if lyophilized: Mix kisspeptin powder with bacteriostatic water per vial instructions (commonly 1–2 mL for 2–5 mg total). Gently roll vial; do not shake. Store reconstituted product at 2–8°C.

3. Draw the dose: Using an insulin or tuberculin syringe (27–31 gauge), draw the calculated volume. Typical concentrations are 50 mcg/0.1 mL.

4. Inject: Pinch skin at injection site, insert needle at 45–90 degree angle, and inject slowly. Release skin and apply light pressure with sterile gauze.

5. Rotate sites: Vary injection sites between abdomen, thighs, and upper arms to minimize injection site reactions (erythema, induration).

6. Timing: Inject at the same time daily (morning or evening) for consistency. Many users report fewer systemic effects when injected in the evening.

Intranasal Administration

1. Prepare: Ensure nasal passages are clear. Blow nose gently or use saline spray if congested.

2. Draw dose: Use provided nasal spray device or atomizer. Typical dose is 1–3 mg per spray.

3. Administer: Insert nozzle into one nostril, close opposite nostril, and spray while inhaling gently. Repeat in opposite nostril if full dose requires two sprays.

4. Wait: Remain upright for 5 minutes post-administration to maximize absorption.

5. Timing: Administer once daily, typically in the morning for consistency.

Cycle Example: Week-by-Week Schedule (Post-Steroid HPTA Recovery)

Day-to-day example (Week 5):

• Monday 7 AM: 100 mcg subcutaneous injection (abdomen)
• Tuesday 7 AM: 100 mcg subcutaneous injection (thigh)
• Wednesday 7 AM: 100 mcg subcutaneous injection (opposite abdomen)
• Continue pattern, rotating sites daily

What to Expect: Timeline of Effects

Hours 0–1 (Immediate)

• Transient flushing: Warmth and redness in face/neck within 15–30 minutes; resolves within 30–60 minutes
• Injection site response: Mild erythema (redness) or warmth; expected and benign
• Libido surge: Rapid increase in sexual arousal and interest, occasionally intense

Days 2–7 (First Week)

• Persistent elevated libido and sexual confidence
• Possible mild headache or transient nausea (especially at higher doses)
• Injection site induration (firm nodule) may develop; resolves over 3–5 days with massage
• LH levels rise measurably (peak response 15–30 min post-injection)

Weeks 2–4 (Building Phase)

• Continued libido elevation; may normalize as body adapts
• Energy and mood improvements correlate with rising testosterone
• Testicular volume and firmness begin to recover (palpable improvement by week 3–4)
• FSH rises in parallel with LH, priming spermatogenesis

Weeks 5–8 (Maintenance Phase)

• Steady state: LH and FSH remain elevated and stable
• Testosterone reaches 60–75% of pre-suppression baseline by week 6–7
• Sexual function fully restored; erections stronger, more frequent
• Sperm parameters show progressive improvement (if monitored)
• Mood, energy, and concentration at peak

Weeks 9–12 (Late Cycle & Taper)

• Potential plateau: LH/FSH and testosterone may stabilize or slightly decline despite dosing (pituitary adaptation)
• Testicular function remains robust; Leydig cell recovery consolidates
• Upon taper (weeks 11–12): minor dip in well-being as doses decrease, but endogenous axis should maintain recovered state
• Post-cycle (weeks 13–20): continued testosterone recovery as hypothalamic GnRH pulsatility fully normalizes

Common Protocol Mistakes

1. Dosing Too High Too Soon

Starting at 150 mcg daily causes excessive LH surges, systemic flushing, and pituitary desensitization. Begin at 50–75 mcg and escalate every 1–2 weeks.

2. Inconsistent Timing

Dosing at random times disrupts pulsatility patterns kisspeptin is designed to preserve. Inject or spray at the same time daily.

3. Skipping the Taper

Abruptly stopping after 10 weeks of daily dosing can briefly suppress endogenous signaling. Taper over 1–2 weeks to support transition.

4. Stacking with Strong GnRH Agonists

Combining kisspeptin with continuous GnRH agonists (e.g., leuprolide) causes excessive suppression or paradoxical receptor desensitization. Avoid concurrent use; stagger if necessary.

5. Poor Injection Technique

Shallow injections, reusing needles, or injecting into lipomas causes site reactions, inflammation, or sterile abscess risk. Use fresh needles; vary sites; inject into subcutaneous tissue, not dermis.

6. Ignoring Reconstitution Guidelines

Using non-bacteriostatic water, over-shaking, or storing reconstituted kisspeptin at room temperature degrades the peptide and reduces efficacy. Use sterile bacteriostatic water; store at 2–8°C; use within 30 days post-reconstitution.

How to Stack with Other Compounds

Stacking with Testosterone Replacement Therapy (TRT)

Protocol: Kisspeptin to restore endogenous production; minimal or no exogenous testosterone during cycle.

• Timing: Begin kisspeptin cycle before TRT; if already on TRT, discontinue exogenous testosterone 2–4 weeks before starting kisspeptin to allow LH/FSH responsiveness to return.
• Dosing: Standard HPTA recovery protocol (50–150 mcg daily).
• Rationale: Kisspeptin's efficacy depends on functional Leydig cells and spermatogonia; exogenous testosterone suppresses their stimulus, negating the recovery effect.

Stacking with HCG (Human Chorionic Gonadotropin)

Protocol: Complementary for testicular preservation and fertility.

• Timing: Concurrent or staggered; HCG directly stimulates Leydig cells (testosterone) while kisspeptin drives FSH (sperm production).
• Dosing: Kisspeptin 100 mcg daily + HCG 250–500 IU 2–3× weekly.
• Rationale: Synergistic; HCG supports testosterone acutely while kisspeptin restores endogenous axis. Effective for preserving fertility during suppression.

Stacking with SARMs (Selective Androgen Receptor Modulators)

Protocol: Not recommended concurrently.

• Rationale: SARMs suppress LH/FSH (though less than anabolics). Stacking creates conflicting signals; use kisspeptin post-SARM cycle for recovery instead.
• Timing: Complete 6–8 week SARM washout before initiating kisspeptin recovery protocol.

Stacking with Peptide GH Secretagogues (GHRP, Ipamorelin, etc.)

Protocol: Compatible; non-interfering.

• Timing: Concurrent dosing acceptable; inject sequentially (5–10 min apart) to separate injection sites.
• Rationale: GH axis is independent of HPG axis; no antagonism or synergy. Both support recovery and anabolism.
• Example: Ipamorelin 200 mcg + kisspeptin 100 mcg daily, separate injections.

Stacking with Aromatase Inhibitors (AI)

Protocol: Use cautiously; minimize AI dosing during kisspeptin cycle.

• Rationale: Estrogen feedback is essential for GnRH pulsatility and axis recovery. Excessive AI use blocks this feedback, reducing kisspeptin efficacy.
• Dosing: If using AI (e.g., anastrozole 0.25–0.5 mg daily), keep dose minimal (or use only if E2 exceeds 50 pg/mL). Prefer monitoring over preemptive suppression.

Protocol Quick Reference

Signs It's Working

• Week 1–2: Increased libido, stronger erections, transient flushing
• Week 3–5: Testicular fullness/size recovery, improved mood and energy
• Week 6–8: Testosterone rising (confirm via bloodwork); semen quality improving if monitored
• Blood markers: LH 5–15 IU/L (elevated), FSH 5–12 I